[HTML][HTML] A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD
EM Kerwin, C Scott-Wilson, L Sanford, S Rennard… - Respiratory …, 2013 - Elsevier
BACKGROUND: Fluticasone furoate (FF)/vilanterol (VI) is a novel once-daily inhaled
corticosteroid/long-acting β2-agonist combination therapy for COPD. We aimed to assess …
corticosteroid/long-acting β2-agonist combination therapy for COPD. We aimed to assess …
[PDF][PDF] A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD
EM Kerwin, C Scott-Wilson, L Sanford… - Respiratory …, 2013 - cyberleninka.org
Summary Background: Fluticasone furoate (FF)/vilanterol (VI) is a novel once-daily inhaled
corticosteroid/long-acting b2-agonist combination therapy for COPD. We aimed to assess …
corticosteroid/long-acting b2-agonist combination therapy for COPD. We aimed to assess …
Corrigendum to “A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD”[Respir Med, 107 (2013) 560e569]
EM Kerwin, C Scott-Wilson, L Sanford, S Rennard… - Respir Med, 2013 - academia.edu
Furthermore, compared with FF 100 μg alone, FF/VI 100/25 μg significantly improved the
adjusted mean wm FEV1 at day 168 by 120 ml (95% CI: 70, 170; p< 0.001)(Table 2).[p. 566 …
adjusted mean wm FEV1 at day 168 by 120 ml (95% CI: 70, 170; p< 0.001)(Table 2).[p. 566 …
A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD
EM Kerwin, C Scott-Wilson, L Sanford, S Rennard… - 2013 - pubmed.ncbi.nlm.nih.gov
Background Fluticasone furoate (FF)/vilanterol (VI) is a novel once-daily inhaled
corticosteroid/long-acting β2-agonist combination therapy for COPD. We aimed to assess …
corticosteroid/long-acting β2-agonist combination therapy for COPD. We aimed to assess …
A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD
EM Kerwin, C Scott-Wilson, L Sanford, S Rennard… - Respiratory …, 2013 - infona.pl
Fluticasone furoate (FF)/vilanterol (VI) is a novel once-daily inhaled corticosteroid/long-
acting β 2-agonist combination therapy for COPD. We aimed to assess the efficacy and …
acting β 2-agonist combination therapy for COPD. We aimed to assess the efficacy and …
Corrigendum to “A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD”[Respir Med, 107 (2013) 560e569]
EM Kerwin, C Scott-Wilson, L Sanford, S Rennard… - Respir Med, 2013 - researchgate.net
Furthermore, compared with FF 100 μg alone, FF/VI 100/25 μg significantly improved the
adjusted mean wm FEV1 at day 168 by 120 ml (95% CI: 70, 170; p< 0.001)(Table 2).[p. 566 …
adjusted mean wm FEV1 at day 168 by 120 ml (95% CI: 70, 170; p< 0.001)(Table 2).[p. 566 …
A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD
EM Kerwin, C Scott-Wilson, L Sanford… - Respiratory …, 2013 - experts.nebraska.edu
Background: Fluticasone furoate (FF)/vilanterol (VI) is a novel once-daily inhaled
corticosteroid/long-acting β 2-agonist combination therapy for COPD. We aimed to assess …
corticosteroid/long-acting β 2-agonist combination therapy for COPD. We aimed to assess …
A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD
EM Kerwin, C Scott-Wilson, L Sanford… - Respiratory …, 2013 - hero.epa.gov
Background: Fluticasone furoate (FF)/vilanterol (VI) is a novel once-daily inhaled
corticosteroid/long-acting β2-agonist combination therapy for COPD. We aimed to assess …
corticosteroid/long-acting β2-agonist combination therapy for COPD. We aimed to assess …
[PDF][PDF] A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD
EM Kerwin, C Scott-Wilson, L Sanford, S Rennard… - Respiratory …, 2013 - core.ac.uk
Summary Background: Fluticasone furoate (FF)/vilanterol (VI) is a novel once-daily inhaled
corticosteroid/long-acting b2-agonist combination therapy for COPD. We aimed to assess …
corticosteroid/long-acting b2-agonist combination therapy for COPD. We aimed to assess …
[HTML][HTML] A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD
EM Kerwin, C Scott-Wilson, L Sanford… - Respiratory …, 2013 - resmedjournal.com
Background Fluticasone furoate (FF)/vilanterol (VI) is a novel once-daily inhaled
corticosteroid/long-acting β 2-agonist combination therapy for COPD. We aimed to assess …
corticosteroid/long-acting β 2-agonist combination therapy for COPD. We aimed to assess …